Nutra Pharma (Nutra Pharma) Momentum Rank : 0 (As of Jun. 14, 2024)

View and export this data going back to . Start your Free Trial

What is Nutra Pharma Momentum Rank?

Nutra Pharma has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Nutra Pharma Momentum Rank Related Terms

Thank you for viewing the detailed overview of Nutra Pharma's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Nutra Pharma (Nutra Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nutra Pharma Corp (OTCPK:NPHC) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1537 NW 65th Avenue, Plantation, FL, USA, 33313

Website

https://www.nutrapharma.com

Nutra Pharma Corp operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. It also develops proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Some of its drug names are Cobroxin, Nyloxin, RPI-78M, RPI-MN and Pet Pain-Away.

Executives

Rik J Deitsch	officer: Chief Executive Officer	4001 NW 73 WAY, CORAL SPRINGS FL 33065
Dan Oran	director	8411 W OAKLAND PARK BLVD, #201, SUNRISE FL 33351
Bruno Sartori	other: Former CFO	275 COMMERCIAL BLVD, STE 260, FT LAUDERDALE FL 33308
Harold Henry Rumph	director, officer: President - ReceptoPharm	1537 N.W. 65TH AVENUE, PLANTATION FL 33313
David Michael Isserman	officer: Chief Marketing Officer	2776 UNIVERSITY DRIVE, CORAL SPRINGS FL 33065
Garry Pottruck	director	10768 NW 18TH CT, CORAL SPRINGS FL 33071
Paul F Reid	director	9610 NW 24 CT, SUNRISE FL 33322
Michael Doherty	director, officer: Executive Chairman
Tanvir A Khandaker	director	387 PARK AVENUE SOUTH THIRD FLOOR, NEW YORK NY 10016
Stewart Alan Lonky	director	1158 CHAUTAUQUA BLVD., PACIFIC PALISADES CA 90272
Stanley Jack Cherelstein	director	2401 SW MANOR HILL DRIVE, PALM CITY FL 34990
Michael Flax	director, officer: Chief Financial Officer	2499 BANYAN RD, BOCA RATON FL 33432
Mcclelland David C Sr	director	P.O. BOX 263, FINDLEY LAKE NY 14736
Mitchell S Felder	director	PO BOX 1332, HERMITAGE PA 16148
Khalsa Soram Singh Md	director	436 N BEDFORD DR, BEVERLY HILLS CA 90210

Nutra Pharma (Nutra Pharma) Headlines

From GuruFocus

Nutra Pharma Partners with NxGen Brands for Nyloxin® Distribution

By Marketwired Marketwired • 04-19-2018